The Trump administration has announced the termination of a multi-billion dollar subsidy program designed to stabilize Medicare Part D prescription drug premiums. The Medicare Part D Premium Stabilization Demonstration, which was initially intended to last at least three years, will now end on January 1, 2027. While federal officials stated that Medicare Part D benefits are not ending, the move has prompted questions regarding potential premium increases for millions of enrollees.
The pilot program was established by the Centers for Medicare and Medicaid Services (CMS) in 2024 to mitigate price increases following the 2022 Inflation Reduction Act. That legislation capped deductibles, which shifted more costs to private insurance companies. To prevent these costs from being passed directly to consumers through high premiums, the government provided approximately $9.8 billion in subsidies to insurance providers. These subsidies limited premium increases to $35 between 2024 and 2025, and $50 for the following cycle.
According to a federal government report, the subsidy program lowered average monthly premiums by approximately $16 this year and $26 in 2025 compared to what they would have been without government intervention. CMS Administrator Dr. Mehmet Oz stated in July that most enrollees can expect premium increases of less than $10 next year. However, Juliette Cubanski of KFF noted that final details regarding specific plan costs and drug coverage lists, known as formularies, will not be available until marketing begins on October 1.
Beyond premiums, enrollees may notice changes in their day-to-day healthcare expenses through adjusted co-pays or changes to which medications their specific plan covers. For example, patients requiring "specialty tier" drugs will continue to pay between 25 percent and 33 percent in co-insurance, but they must verify if their specific medications remain on their plan's list for the upcoming year. The change does not affect durable medical equipment like hospital beds or oxygen, which are covered under Medicare Part B, nor does it impact the Medicare GLP-1 Bridge program, which maintains a $50 copay for weight-loss medications through late 2027.
The termination of this program sets a precedent for how the federal government manages the cost-sharing balance between private insurers and beneficiaries under the Inflation Reduction Act’s new framework. Medicare recipients will first see the effects of these changes during the fall open enrollment period, which runs from October 15 to December 7. During this time, beneficiaries can compare plans to determine if they need to switch providers to maintain affordable access to their prescriptions. More specific pricing data is expected from CMS in September.
Beyond premiums, enrollees may notice changes in their day-to-day healthcare expenses through adjusted co-pays or changes to which medications their specific plan covers. For example, patients requiring "specialty tier" drugs will continue to pay between 25 percent and 33 percent in co-insurance, but they must verify if their specific medications remain on their plan's list for the upcoming year. The change does not affect durable medical equipment like hospital beds or oxygen, which are covered under Medicare Part B, nor does it impact the Medicare GLP-1 Bridge program, which maintains a $50 copay for weight-loss medications through late 2027.
The termination of this program sets a precedent for how the federal government manages the cost-sharing balance between private insurers and beneficiaries under the Inflation Reduction Act’s new framework. Medicare recipients will first see the effects of these changes during the fall open enrollment period, which runs from October 15 to December 7. During this time, beneficiaries can compare plans to determine if they need to switch providers to maintain affordable access to their prescriptions. More specific pricing data is expected from CMS in September.